Patheon markets transatlantic cov-lite for DSM merger
Toronto-listed pharmaceuticals firm Patheon is in the market for a $1.15bn-equivalent seven year covenant-lite loan package.
The transatlantic deal will back the merger of Patheon with DSM Pharmaceutical Products, Royal DSM’s pharmaceutical business, as announced in November.Private equity firm ...
Please take a trial or subscribe to access this content.
Contact Mark Goodes to discuss your access: email@example.com